Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
Agenus (AGEN) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.05. This compares to a loss of $1 per share a year ago.
Do Options Traders Know Something About Agenus Stock We Don't?
Investors need to pay close attention to AGEN stock based on the movements in the options market lately.
AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot
Agenus surges after securing up to $340M in financing to fund its phase III ROBBIN colon cancer study and extend its cash runway if warrants are exercised.
Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last?
Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS Colon Cancer Transcript
Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS Colon Cancer Transcript
Agenus shares surge as company secures up to $340M to advance colon cancer trial
Agenus (Agenus Inc (NASDAQ:AGEN)) shares jumped about 100% on Monday after the biotechnology company announced an oversubscribed private placement of up to $340 million to support development of its botensilimab and balstilimab (BOT+BAL) immunotherapy combination in microsatellite-stable (MSS) colon cancer. The financing includes approximately $85 million in upfront gross proceeds, with an additional potential $255 million available through the full exercise of purchase warrants.
Agenus Pivots to Phase 3 Colon Cancer Trial, Lines Up $340 Million Financing
Agenus NASDAQ: AGEN said it is shifting its development focus and financial resources toward a Phase 3 registrational trial of neoadjuvant botensilimab plus balstilimab, known as BOT/BAL, in high-risk stage 2 and stage 3 microsatellite stable colon cancer.
Agenus Annual Meeting: BOT/BAL Leads Cancer Drug Push as Balance Sheet Improves
Agenus NASDAQ: AGEN told shareholders at its 2026 virtual annual meeting that it remains focused on advancing its botensilimab and balstilimab immunotherapy combination, known as BOT/BAL, while working to strengthen its financial position and pursue regulatory pathways in the United States and Europe.
Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report?
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock?
AGEN Early Access Revenues Signal a New Path Ahead of Approval
Agenus turns early physician demand for BOT+BAL into revenues and real-world data, testing its launch strategy before formal approval.
Is Agenus Stock a Hold Amid Valuation and Funding Risks?
AGEN trades below peers on sales multiples, but BOT+BAL's promise is offset by funding needs, dilution risk and a going-concern warning.
AGEN BOT+BAL: What the BATTMAN Trial Means for mCRC
Agenus bets on BOT+BAL in MSS mCRC, and the phase III BATTMAN trial determines whether early survival signals translate into a pivotal win.
